202 related articles for article (PubMed ID: 18227490)
1. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?
Stirban AO; Tschoepe D
Diabetes Care; 2008 Feb; 31 Suppl 2():S226-8. PubMed ID: 18227490
[TBL] [Abstract][Full Text] [Related]
2. Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
Wienbergen H; Senges J; Gitt AK
Diabetes Care; 2008 Feb; 31 Suppl 2():S222-5. PubMed ID: 18227489
[No Abstract] [Full Text] [Related]
3. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Ruiz J; Egli M
Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
[TBL] [Abstract][Full Text] [Related]
4. [Factors that influence the implementation of the guidelines for aspirin use by diabetic patients in Israel].
Azuz N; Thomas K; Yaffe Y; Katz M; Weingarten M; Matalon A
Harefuah; 2008 Dec; 147(12):971-4, 1030. PubMed ID: 19260592
[TBL] [Abstract][Full Text] [Related]
5. Do people with diabetes need statins?
White JR
Diabetes Educ; 2008; 34(4):664-73. PubMed ID: 18669808
[TBL] [Abstract][Full Text] [Related]
6. Initiating statins in the elderly: the evolving challenge.
Walker DB; Jacobson TA
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):182-7. PubMed ID: 18316955
[TBL] [Abstract][Full Text] [Related]
7. [Statins with a perspective of lifelong therapy].
Ertaş FS
Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
[TBL] [Abstract][Full Text] [Related]
8. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
9. The polypill to prevent cardiovascular disease: physicians' perspectives.
Viera AJ
Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
[TBL] [Abstract][Full Text] [Related]
10. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
11. Polypill holds promise for people with chronic disease.
Wise J
Bull World Health Organ; 2005 Dec; 83(12):885-7. PubMed ID: 16462975
[No Abstract] [Full Text] [Related]
12. Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
Green LW
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S4-8; discussion S9. PubMed ID: 16052194
[TBL] [Abstract][Full Text] [Related]
13. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
14. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
Ali YS; Linton MF; Fazio S
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):142-6. PubMed ID: 18316949
[TBL] [Abstract][Full Text] [Related]
15. [The polypill: not an effective strategy for reduction of cardiovascular disease].
Westerweel PE; van Wijk JP; Verhaar MC
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
Wald DS; Wald NJ
J Eval Clin Pract; 2012 Jun; 18(3):612-5. PubMed ID: 21276141
[TBL] [Abstract][Full Text] [Related]
17. Requirement of pharmacological treatment for primary prevention of cardiovascular disease in asymptomatic office-executives in north-India.
Kasliwal RR; Bansal M; Mehrotra R; Agrawal V; Shrivastava S
Indian Heart J; 2010; 62(4):324-9. PubMed ID: 21280473
[TBL] [Abstract][Full Text] [Related]
18. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cardiovascular events in diabetes.
Sigal R; Malcolm J; Meggison H
Clin Evid; 2004 Jun; (11):777-806. PubMed ID: 15652037
[No Abstract] [Full Text] [Related]
20. Lipid-lowering therapy today: treating the high-risk cardiovascular patient.
Berra K
J Cardiovasc Nurs; 2008; 23(5):414-21. PubMed ID: 18728514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
